{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:30Z","timestamp":1791260730880,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["PR9"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Pharmacological approaches are frequently proposed in fibromyalgia, based on different rationale. Some treatments are proposed to alleviate symptoms, mainly pain, fatigue, and sleep disorder. Other treatments are proposed according to pathophysiological mechanisms, especially central sensitization and abnormal pain modulation. Globally, pharmacological approaches are weakly effective but market authorization differs between Europe and United States. Food and Drug Administration\u2013approved medications for fibromyalgia treatment include serotonin and noradrenaline reuptake inhibitors, such as duloxetine, and pregabalin (an anticonvulsant), which target neurotransmitter modulation and central sensitization. Effect of analgesics, especially tramadol, on pain is weak, mainly on short term. Low-dose naltrexone and ketamine are gaining attention due their action on neuroinflammation and depression modulation, but treatment protocols have not been validated. Moreover, some treatments should be avoided due to the high risk of abuse and severe side effects, especially opioids, steroids, and hormonal replacement.<\/jats:p>","DOI":"10.1097\/pr9.0000000000001222","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:00:56Z","timestamp":1736863256000},"page":"e1222","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Fibromyalgia: do I tackle you with pharmacological treatments?"],"prefix":"10.1097","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0509-1592","authenticated-orcid":false,"given":"Serge","family":"Perrot","sequence":"first","affiliation":[{"name":"Pain Department, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris Cit\u00e9 University, INSERM U987, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2]]},"reference":[{"key":"R1-20250128","doi-asserted-by":"crossref","first-page":"e0012","DOI":"10.5041\/RMMJ.10239","article-title":"Attitudes of Israeli rheumatologists to the use of medical cannabis as therapy for rheumatic disorders","volume":"7","author":"Ablin","year":"2016","journal-title":"Rambam Maimonides Med J"},{"key":"R2-20250128","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s10067-022-06129-8","article-title":"Comparative efficacy of amitriptyline, duloxetine and pregabalin for treating fibromyalgia in adults: an overview with network meta-analysis","volume":"41","author":"Alberti","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R3-20250128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4081\/reumatismo.2021.1362","article-title":"The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia Best practices based on current scientific evidence","volume":"73","author":"Ariani","year":"2021","journal-title":"Reumatismo"},{"key":"R4-20250128","doi-asserted-by":"crossref","first-page":"1275921","DOI":"10.3389\/fnins.2023.1275921","article-title":"Interplay between noxious heat sensitivity and temporal summation magnitude in patients with fibromyalgia and long-term opioid use","volume":"17","author":"Bao","year":"2023","journal-title":"Front Neurosci"},{"key":"R5-20250128","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0002-9343(03)00116-5","article-title":"Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study","volume":"114","author":"Bennett","year":"2003","journal-title":"Am J Med"},{"key":"R6-20250128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/RHU.0000000000001273","article-title":"Opioid use in fibromyalgia continues despite guidelines that do not support its efficacy or risk","volume":"27","author":"Bruce","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R7-20250128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/ph15060675","article-title":"Pharmacovigilance signals of the opioid epidemic over 10 years: data mining methods in the analysis of pharmacovigilance datasets collecting Adverse Drug Reactions (ADRs) reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R8-20250128","first-page":"CD012188","article-title":"Gabapentin for fibromyalgia pain in adults","volume":"1","author":"Cooper","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R9-20250128","first-page":"CD008244","article-title":"Milnacipran for pain in fibromyalgia in adults","volume":"2015","author":"Cording","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20250128","doi-asserted-by":"crossref","first-page":"e13455","DOI":"10.1111\/ijcp.13455","article-title":"Tramadol for management of fibromyalgia pain and symptoms: systematic review","volume":"74","author":"da Rocha","year":"2020","journal-title":"Int J Clin Pract"},{"key":"R11-20250128","first-page":"CD012332","article-title":"Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults","volume":"3","author":"Derry","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R12-20250128","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S2665-9913(23)00278-3","article-title":"Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial","volume":"6","author":"Due Bruun","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"R13-20250128","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/GH9.0000000000000093","article-title":"Duloxetine: an effective treatment for fibromyalgia syndrome?","volume":"6","author":"Elahi","year":"2023","journal-title":"Int J Surg Global Health"},{"key":"R14-20250128","first-page":"898493","article-title":"Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study","volume":"2013","author":"Fitzcharles","year":"2013","journal-title":"Pain Res Treat"},{"key":"R15-20250128","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s40265-021-01602-1","article-title":"Cannabis-based medicines and medical cannabis in the treatment of nociplastic pain","volume":"81","author":"Fitzcharles","year":"2021","journal-title":"Drugs"},{"key":"R16-20250128","first-page":"1029","article-title":"Influence of tramadol on neurotransmitter systems of the rat brain","volume":"46","author":"Frink","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"R17-20250128","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.mayocp.2016.02.002","article-title":"Opioid use in fibromyalgia: a cautionary tale","volume":"91","author":"Goldenberg","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"R18-20250128","doi-asserted-by":"crossref","first-page":"25532","DOI":"10.52965\/001c.25532","article-title":"Milnacipran for the treatment of fibromyalgia","volume":"9","author":"Gupta","year":"2021","journal-title":"Health Psychol Res"},{"key":"R19-20250128","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/AJP.0000000000000738","article-title":"Insomnia increases symptom severity and health care utilization in patients with fibromyalgia: a population-based study","volume":"35","author":"Huang","year":"2019","journal-title":"Clin J Pain"},{"key":"R20-20250128","first-page":"e17332","article-title":"A systematic review of fibromyalgia and recent advancements in treatment: is medicinal cannabis a new hope?","volume":"13","author":"Khurshid","year":"2021","journal-title":"Cureus"},{"key":"R21-20250128","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/acr.25142","article-title":"Efficacy and safety of sublingual cyclobenzaprine for the treatment of fibromyalgia: results from a randomized, double-blind, placebo-controlled trial","volume":"75","author":"Lederman","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R22-20250128","first-page":"CD007115","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","volume":"2014","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R23-20250128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/annrheumdis-2016-209724","article-title":"EULAR revised recommendations for the management of fibromyalgia","volume":"76","author":"Macfarlane","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R24-20250128","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ejpain.2011.03.008","article-title":"Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial","volume":"15","author":"Noppers","year":"2011","journal-title":"Eur J Pain"},{"key":"R25-20250128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.31486\/toj.21.0038","article-title":"Systematic review of the use of intravenous ketamine for fibromyalgia","volume":"21","author":"Pastrak","year":"2021","journal-title":"Ochsner J"},{"key":"R26-20250128","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/ejp.564","article-title":"More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: a meta-analysis examining six core symptoms","volume":"18","author":"Perrot","year":"2014","journal-title":"Eur J Pain"},{"key":"R27-20250128","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/ejp.1367","article-title":"Fibromyalgia: a misconnection in a multiconnected world?","volume":"23","author":"Perrot","year":"2019","journal-title":"Eur J Pain"},{"key":"R28-20250128","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1586\/14737175.2015.1091726","article-title":"Amitriptyline for the treatment of fibromyalgia: a comprehensive review","volume":"15","author":"Rico-Villademoros","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"R29-20250128","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1080\/1744666X.2019.1665997","article-title":"Medical cannabis and cannabinoids in rheumatology: where are we now?","volume":"15","author":"Sarzi-Puttini","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"R30-20250128","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jpain.2010.09.007","article-title":"Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia","volume":"12","author":"Siler","year":"2011","journal-title":"J Pain"},{"key":"R31-20250128","first-page":"1786","article-title":"Ozone therapy in 65 patients with fibromyalgia: an effective therapy","volume":"23","author":"Tirelli","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R32-20250128","doi-asserted-by":"crossref","DOI":"10.1515\/sjpain-2023-0141","article-title":"Healthcare experiences of fibromyalgia patients and their associations with satisfaction and pain relief: a patient survey","volume":"24","author":"Wigers","year":"2024","journal-title":"Scand J Pain"},{"key":"R33-20250128","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2147\/JPR.S395457","article-title":"The safety and efficacy of low-dose naltrexone in patients with fibromyalgia: a systematic review","volume":"16","author":"Yang","year":"2023","journal-title":"J Pain Res"}],"container-title":["PAIN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PR9.0000000000001222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T20:03:52Z","timestamp":1738094632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PR9.0000000000001222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pr9.0000000000001222","relation":{},"ISSN":["2471-2531"],"issn-type":[{"value":"2471-2531","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"2024-07-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}